Vaginal oxygen and hyaluronic acid for genito-urinary symptoms of breast cancer survivors. One-year follow-up study

Backgrounds To investigate in breast cancer survivors on adjuvant hormone therapy the persistence up to 1 year of the modifications of genito-urinary symptoms associated with the use of vaginal oxygen and hyaluronic acid. Methods Single centre prospective observational study with a follow-up period of 12 months performed on women enrolled between July 2020 and July 2024. Each woman every 15 days for 5 times received an applications of vaginal oxygen and hyaluronic acid. At each single treatment intravaginal oxygen was administered for 15 min. In the last 5 min oxygen was co-administered with a 0.2% sodium hyalurate solution. Modifications associated with treatments were evaluated at the end of treatment and 1, 3 and 12 months since treatment termination. The modification of the vaginal health index score (VHIS) was the primary objective of the study. Secondary objectives were modifications of the visual analogue scale value (VAS) of vaginal burning and dyspareunia, of the female sexual function inventory score (FSFI) and of the short-form of the urinary distress inventory-6 score (UDI-6). Results Sixty-five breast cancer survivors were included between July 2021 and July 2024. During treatment we observed an improvement ( p = 0.005) of VHIS and FSFI, and a decrease ( p = 0.005) of dyspareunia, burning and UDI-6 score. After 12 months VHIS (13.4 ± 2.5 vs. 9.6 ± 2.5) and FSFI (13.9 ± 9.5 vs. 10.0 ± 7.4), remained higher ( p = 0.005), dyspareunia (6.5 ± 2.8 vs. 8.7 ± 1.4 p = 0.005) and burning (3.4 ± 3.1 vs. 6.1 ± 2.7) lower ( p = 0.005) than at baseline, while the UDI-6 scores returned to baseline values. Conclusions Genito-urinary symptoms of breast cancer survivors on adjuvant endocrine therapy improved following vaginal oxygen and hyaluronic acid. After 12 months improvements were conserved on sexuality, attenuated on vaginal atrophy, dyspareunia and vaginal burning, and lost on lower urinary tract disturbances.

Authors

Institutions

Publication Details

Journal
Frontiers in Reproductive Health
Published
2026-11-20
DOI
https://doi.org/10.3389/frph.2026.1995703
Primary Topic
Menopause: Health Impacts and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Vaginal oxygen and hyaluronic acid for genito-urinary symptoms of breast cancer survivors. One-year follow-up study

Del Mastro L, Giorgia Asinaro, Angelo Cagnacci, Claudia Massarotti et al.
4 links
Frontiers in Reproductive Health
Menopause: Health Impacts and Treatments
article

Vaginal oxygen and hyaluronic acid for genito-urinary symptoms of breast cancer survivors. One-year follow-up study

Del Mastro L, Giorgia Asinaro, Angelo Cagnacci, Claudia Massarotti, Ambrogio Pietro Londero, Matteo Lambertini, Giorgia Spirito-Rosevich
article en

Abstract

Backgrounds To investigate in breast cancer survivors on adjuvant hormone therapy the persistence up to 1 year of the modifications of genito-urinary symptoms associated with the use of vaginal oxygen and hyaluronic acid. Methods Single centre prospective observational study with a follow-up period of 12 months performed on women enrolled between July 2020 and July 2024. Each woman every 15 days for 5 times received an applications of vaginal oxygen and hyaluronic acid. At each single treatment intravaginal oxygen was administered for 15 min. In the last 5 min oxygen was co-administered with a 0.2% sodium hyalurate solution. Modifications associated with treatments were evaluated at the end of treatment and 1, 3 and 12 months since treatment termination. The modification of the vaginal health index score (VHIS) was the primary objective of the study. Secondary objectives were modifications of the visual analogue scale value (VAS) of vaginal burning and dyspareunia, of the female sexual function inventory score (FSFI) and of the short-form of the urinary distress inventory-6 score (UDI-6). Results Sixty-five breast cancer survivors were included between July 2021 and July 2024. During treatment we observed an improvement ( p = 0.005) of VHIS and FSFI, and a decrease ( p = 0.005) of dyspareunia, burning and UDI-6 score. After 12 months VHIS (13.4 ± 2.5 vs. 9.6 ± 2.5) and FSFI (13.9 ± 9.5 vs. 10.0 ± 7.4), remained higher ( p = 0.005), dyspareunia (6.5 ± 2.8 vs. 8.7 ± 1.4 p = 0.005) and burning (3.4 ± 3.1 vs. 6.1 ± 2.7) lower ( p = 0.005) than at baseline, while the UDI-6 scores returned to baseline values. Conclusions Genito-urinary symptoms of breast cancer survivors on adjuvant endocrine therapy improved following vaginal oxygen and hyaluronic acid. After 12 months improvements were conserved on sexuality, attenuated on vaginal atrophy, dyspareunia and vaginal burning, and lost on lower urinary tract disturbances.

Frontiers in Reproductive HealthVol. 8
Istituto Giannina Gaslini (IT), Ospedale Policlinico San Martino (IT), University of Genoa (IT)
Good health and well-being
Menopause: Health Impacts and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon